Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Preventing glial cell graft rejection with a T cell-targeting immunotherapy

September 18, 2019 8:09 PM UTC

INDICATION: Neurology

Stimulating CTLA-4 signaling and inhibiting CD40L could prevent rejection of glial cell allografts for demyelinating diseases. In co-culture with primary mouse glial-restricted progenitor cells, T cells from mice treated with the CTLA-4-Ig fusion protein abatacept plus an anti-CD40L mAb proliferated less, indicating reduced anti-glial cell immune response, than T cells from untreated mice. The CTLA-4 and CD40L-based therapy extended survival of engrafted glial-restricted progenitor cells and promoted myelin sheath formation within the corpus callosum in a mouse model of demyelination...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article